Welcome to the Newsroom
18 August 2016
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), has provided an update on the Company’s cash position and the recruitment progress in its two active clinical trials in IMP321.
As a result of careful financial management, Prima remains in a solid financial position, with approximately A$20M cash as of 30 June 2016. Based on the Company’s forecasts, the current operational cash reach has been extended well into the fourth quarter of 2017.
Article as pdf